ACR Stock Overview
Engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Acrux Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.033 |
| 52 Week High | AU$0.099 |
| 52 Week Low | AU$0.03 |
| Beta | 1.22 |
| 1 Month Change | 0% |
| 3 Month Change | -36.54% |
| 1 Year Change | -46.77% |
| 3 Year Change | -70.00% |
| 5 Year Change | -80.00% |
| Change since IPO | -96.33% |
Recent News & Updates
Recent updates
Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet
Nov 16
It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year
Nov 16We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully
Sep 21Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation
May 20Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?
Feb 04Here's What We Think About Acrux's (ASX:ACR) CEO Pay
Dec 14
Shareholder Returns
| ACR | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 4.8% | 0.6% | 0.2% |
| 1Y | -46.8% | -4.9% | 8.4% |
Return vs Industry: ACR underperformed the Australian Pharmaceuticals industry which returned -4.9% over the past year.
Return vs Market: ACR underperformed the Australian Market which returned 8.4% over the past year.
Price Volatility
| ACR volatility | |
|---|---|
| ACR Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.4% |
| 10% least volatile stocks in AU Market | 2.9% |
Stable Share Price: ACR has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: ACR's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Michael Kotsanis | www.acrux.com.au |
Acrux Limited, together with its subsidiaries, engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; Dapsone 5% and Dapsone 7.5% which are gels for the treatment of acne vulgaris; and Prilocaine 2.5% and Lidocaine 2.5%, a topical anaesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain caused by chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores.
Acrux Limited Fundamentals Summary
| ACR fundamental statistics | |
|---|---|
| Market cap | AU$12.87m |
| Earnings (TTM) | -AU$5.80m |
| Revenue (TTM) | AU$5.09m |
2.6x
P/S Ratio-2.3x
P/E RatioIs ACR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACR income statement (TTM) | |
|---|---|
| Revenue | AU$5.09m |
| Cost of Revenue | AU$6.38m |
| Gross Profit | -AU$1.28m |
| Other Expenses | AU$4.52m |
| Earnings | -AU$5.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.014 |
| Gross Margin | -25.22% |
| Net Profit Margin | -113.93% |
| Debt/Equity Ratio | 45.4% |
How did ACR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 16:22 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Acrux Limited is covered by 12 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dennis Hulme | APP Securities Pty Ltd. |
| John Hester | Bell Potter |
| Matthijs Smith | Canaccord Genuity |